J.P. Morgan Health Conference - Day 3 Highlights
- Jonathan Poyer
- Jan 11, 2024
- 1 min read
Day 3 was pretty quiet. Macro CPI print dominated the tape this morning with the hot number driving some risk off in biotech.
WSJ published an updated headline that NVS may be backing away from a CYTK deal >$10 billion.
We expect some consolidation into earnings season and expected follow-on offering activity for development stage companies.
Yorumlar